Registration
On-demand webcast
Chaired by Mohamad Mohty with Graham Jackson, María-Victoria Manteca, Suzanne Trudel and Salomon Manier, this 1hour 45 minute webcast focuses on providing you with the best decision-making tools to select the optimal therapy for patients with relapsed-refractory multiple myeloma (RRMM). After taking part in the educational activity, you will know who, when, and how to treat RRMM.
Agenda
|
Session |
Speaker |
|---|---|
|
Welcome and introduction |
Mohamad Mohty |
|
Relapse definition and timing of therapy |
Graham Jackson |
|
Optimal sequencing of therapy at first relapse |
Mohamad Mohty |
|
Optimal sequencing of therapy beyond first relapse |
María-Victoria Mateos |
|
Trial results of anti-CD38 and bispecific antibodies |
Salomon Manier |
|
Trial results of conjugated antibodies |
Suzanne Trudel |
|
Live faculty Q&A |
All |
|
Summary and close |
Mohamad Mohty |
Target Audience
Hematologists, oncologists, oncology nurses, and all other HCPs managing RRMM
Learning objectives
After participating in the webcast you will be able to:
- • Describe the advances in therapeutic targets in RRMM and the associated novel agents
- • Select optimal and individualized treatment strategies for patients with RRMM
Accreditation
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Educational grant
This independent educational activity was supported by an educational grant from GlaxoSmithKline.
Registration
Contact us
Email: IME@springer.com
Address: Springer Healthcare IME The Campus, 4 Crinan Street London, N1 9XW, UK